Chronic Wounds Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Paracrine, Inc, Oneness Biotech, MediWound, PolarityTE

Chronic Wounds Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight |  Paracrine, Inc, Oneness Biotech, MediWound, PolarityTE
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Chronic Wounds pipeline constitutes 7+ key companies continuously working towards developing 8+ Chronic Wounds treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Chronic Wounds Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Wounds Market.


Some of the key takeaways from the Chronic Wounds Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Chronic Wounds treatment therapies with a considerable amount of success over the years. 

  • Chronic Wounds companies working in the treatment market are Paracrine, Inc, Oneness Biotech, MediWound, PolarityTE, and others, are developing therapies for the Chronic Wounds treatment 

  • Emerging Chronic Wounds therapies in the different phases of clinical trials are- ADRCs, ON101, EscharEx, SkinTE, and others are expected to have a significant impact on the Chronic Wounds market in the coming years.   

  • In March 2024, SOLASCURE revealed the release of its CLEANVLU Phase IIa clinical trial findings in the esteemed International Wound Journal, a prominent publication in the wound care field. SolasCure’s debut investigational solution, Aurase Wound Gel, comprises a hydrogel that dispenses tarumase (temporary INN), an engineered enzyme sourced from medical maggots. The gel is designed to facilitate wound healing by promoting debridement and preparing the wound bed for recovery.

  • In February 2024, Cynata Therapeutics Limited has concluded the preliminary assessment of wound size across the initial 16 participants in its phase 1 clinical study of CYP-006TK for diabetic foot ulcers (DFU), spanning up to the 10-week post-treatment evaluation.

  • In February 2024, PolarityTE has commenced a multi-center, prospective, randomized controlled trial to assess the effectiveness and safety of SkinTE® in treating Wagner 1 diabetic foot ulcers (DFUs), known as COVER DFUs II. The trial aims to evaluate the closure achieved through vascularized epithelial regeneration with SkinTE® for Wagner grade 1 DFUs.

  • In May 2022, PolarityTE revealed that SkinTE has been awarded a Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) under the company’s open Investigational New Drug (IND) application.


Chronic Wounds Overview

Chronic wounds are injuries to the skin that fail to progress through the normal stages of healing within an expected timeframe, typically within three months. These wounds often remain open for an extended period, leading to persistent inflammation and delayed healing. Common types of chronic wounds include pressure ulcers, diabetic foot ulcers, venous ulcers, and arterial ulcers.


Get a Free Sample PDF Report to know more about Chronic Wounds Pipeline Therapeutic Assessment-


Emerging Chronic Wounds Drugs Under Different Phases of Clinical Development Include:

  • ADRCs: Paracrine, Inc

  • ON101: Oneness Biotech

  • EscharEx: MediWound

  • SkinTE: PolarityTE


Chronic Wounds Route of Administration

Chronic Wounds pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical


Chronic Wounds Molecule Type

Chronic Wounds Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy 


Chronic Wounds Pipeline Therapeutics Assessment

  • Chronic Wounds Assessment by Product Type

  • Chronic Wounds By Stage and Product Type

  • Chronic Wounds Assessment by Route of Administration

  • Chronic Wounds By Stage and Route of Administration

  • Chronic Wounds Assessment by Molecule Type

  • Chronic Wounds by Stage and Molecule Type


DelveInsight’s Chronic Wounds Report covers around 5+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration


Further Chronic Wounds product details are provided in the report. Download the Chronic Wounds pipeline report to learn more about the emerging Chronic Wounds therapies


Some of the key companies in the Chronic Wounds Therapeutics Market include:

Key companies developing therapies for Chronic Wounds are – ConvaTec Inc., Smith & Nephew, 3M, and others.


Chronic Wounds Pipeline Analysis:

The Chronic Wounds pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Wounds with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Wounds Treatment.

  • Chronic Wounds key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Chronic Wounds Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Wounds market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Chronic Wounds drugs and therapies


Chronic Wounds Pipeline Market Drivers

  • The drivers of the chronic wound care market include factors such as the increasing prevalence of chronic diseases like diabetes, cancer, and autoimmune diseases, the growing elderly population, the rise in sports related injuries, and the need for advanced wound care products and treatments.


Chronic Wounds Pipeline Market Barriers

  • With a limited patient population, pharmaceutical companies face challenges in recouping the substantial expenses incurred during the research, development, and clinical trial phases of new treatments.


Scope of Chronic Wounds Pipeline Drug Insight    

  • Coverage: Global

  • Key Chronic Wounds Companies: Paracrine, Inc, Oneness Biotech, MediWound, PolarityTE, and others

  • Key Chronic Wounds Therapies: ADRCs, ON101, EscharEx, SkinTE, and others

  • Chronic Wounds Therapeutic Assessment: Chronic Wounds current marketed and Chronic Wounds emerging therapies

  • Chronic Wounds Market Dynamics: Chronic Wounds market drivers and Chronic Wounds market barriers 


Request for Sample PDF Report for Chronic Wounds Pipeline Assessment and clinical trials


Table of Contents

1. Chronic Wounds Report Introduction

2. Chronic Wounds Executive Summary

3. Chronic Wounds Overview

4. Chronic Wounds- Analytical Perspective In-depth Commercial Assessment

5. Chronic Wounds Pipeline Therapeutics

6. Chronic Wounds Late Stage Products (Phase II/III)

7. Chronic Wounds Mid Stage Products (Phase II)

8. Chronic Wounds Early Stage Products (Phase I)

9. Chronic Wounds Preclinical Stage Products

10. Chronic Wounds Therapeutics Assessment

11. Chronic Wounds Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Wounds Key Companies

14. Chronic Wounds Key Products

15. Chronic Wounds Unmet Needs

16 . Chronic Wounds Market Drivers and Barriers

17. Chronic Wounds Future Perspectives and Conclusion

18. Chronic Wounds Analyst Views

19. Appendix

20. About DelveInsight



About DelveInsight


DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States